Tactile Systems Technology, Inc. Earnings Recaps
Q1 2026
May 5, 2026
Tactile Systems delivered better-than-expected revenue and margin growth, driving a 5.1% stock increase. Strength in Medicare-driven advanced pump sales and successful operational execution on prior authorization rollout supported upside.
Key takeaways
- Total revenue rose 23% year over year to $75.3 million in Q1 2026.
- Lymphedema revenue grew 23% to $62.2 million, led by Flexitouch sales benefiting from updated Medicare NCD policy.
- Medicare channel sales surged 40% year over year, reflecting both policy tailwinds and some order acceleration before new prior authorization rules.
- Gross margin expanded by 250 basis points to 76.5%, supporting adjusted EBITDA growth by $4 million to $3.7 million.
- Management accelerated AI prior authorization technology rollout to address new Medicare requirements, demonstrating operational readiness amid early implementation challenges.
Q3 2025
Nov 4, 2025
Tactile Medical reported robust third-quarter results with total revenue of $85.8 million, achieving a 17% year-over-year increase, driven by significant growth in both lymphedema and airway clearance segments. The company raised its full-year revenue guidance amid strong operational progress and an expanded field sales team.
Key takeaways
- Total revenue grew 17% year-over-year to $85.8 million; lymphedema revenue up 11% and airway clearance revenue surged 71%.
- Adjusted EBITDA rose 34% year-over-year to $14.4 million, reflecting improved profitability.
- Strengthened field sales organization achieved record headcount of 329 reps, supporting market demand effectively.
- Significant growth in the Medicare payer channel, up 130% year-over-year, helped drive recovery in lymphedema sales.
- Updated full-year revenue guidance raised to $317-$321 million, indicating an 8% to 10% growth outlook.